Actualités Generation Uranium Inc - GEN | Actions TSX Venture Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Agreement for Daratumumab Receives Antitrust Clearance

Company Announcement Daratumumab license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson...

Additional Details Concerning Issue of Shares to Johnson & Johnson Development Corporation as Part of the Daratumumab Agreement

Company Announcement Johnson & Johnson Development Corporation to subscribe to 5.4 million shares of nominally DKK 1 at a price of DKK 88...

Genmab Enters Worldwide Agreement With Janssen for Daratumumab

Company Announcement Genmab licenses daratumumab to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson...

Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance

COPENHAGEN, Denmark, Aug. 15, 2012 (GLOBE NEWSWIRE) -- Interim Report for the First Half 2012 DuoBody™ collaborations signed with Novartis...

Arzerra Second Quarter 2012 Net Sales Figures

Company Announcement Arzerra worldwide net sales in Q2 2012 totaled GBP 14.9 million Genmab expects royalty payment of DKK 27 million...

Genmab Announces Interim Results of Ofatumumab Phase II Study in Multiple Sclerosis

COPENHAGEN, Denmark, July 6, 2010 (GLOBE NEWSWIRE) -- Summary: Genmab announces interim results from a Phase II study of ofatumumab in...

GlaxoSmithKline and Genmab Announce Amendment to Ofatumumab Agreement

COPENHAGEN, Denmark, July 1, 2010 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab announce an amendment to the ofatumumab co-development and...

Genmab Announces Change in Management

COPENHAGEN, Denmark, June 15, 2010 (GLOBE NEWSWIRE) -- Summary: Dr. Lisa N. Drakeman retires from her position as Chief Executive and as member...

Genmab Presents Data From a Pivotal Trial of Zalutumumab Versus Best Supportive Care in Patients With Refractory Head and Neck C

COPENHAGEN, Denmark, June 7, 2010 (GLOBE NEWSWIRE) -- Summary: Data presented at ASCO from the first controlled study to demonstrate that an...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Generation Uranium Inc (GEN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

GEN Actualités

Agreement for Daratumumab Receives Antitrust Clearance

Additional Details Concerning Issue of Shares to Johnson & Johnson Development Corporation as Part of the Daratumumab Agreement

Genmab Enters Worldwide Agreement With Janssen for Daratumumab

Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance

Arzerra Second Quarter 2012 Net Sales Figures

Genmab Announces Interim Results of Ofatumumab Phase II Study in Multiple Sclerosis

GlaxoSmithKline and Genmab Announce Amendment to Ofatumumab Agreement

Genmab Announces Change in Management

Genmab Presents Data From a Pivotal Trial of Zalutumumab Versus Best Supportive Care in Patients With Refractory Head and Neck C

Change in Constitution of the Board of Directors

Genmab Announces 2010 First Quarter Results

Arzerra First Quarter 2010 Net Sales Figures

Passing of Genmab A/S' Annual General Meeting

Genmab Announces Pipeline and Technology Update

GlaxoSmithKline Receives Conditional Marketing Authorization in the EU for Arzerra(TM) (ofatumumab)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Generation Uranium Inc (GEN) Actualités

Generation Uranium Inc (GEN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

GEN Actualités

Agreement for Daratumumab Receives Antitrust Clearance

Additional Details Concerning Issue of Shares to Johnson & Johnson Development Corporation as Part of the Daratumumab Agreement

Genmab Enters Worldwide Agreement With Janssen for Daratumumab

Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance

Arzerra Second Quarter 2012 Net Sales Figures

Genmab Announces Interim Results of Ofatumumab Phase II Study in Multiple Sclerosis

GlaxoSmithKline and Genmab Announce Amendment to Ofatumumab Agreement

Genmab Announces Change in Management

Genmab Presents Data From a Pivotal Trial of Zalutumumab Versus Best Supportive Care in Patients With Refractory Head and Neck C

Change in Constitution of the Board of Directors

Genmab Announces 2010 First Quarter Results

Arzerra First Quarter 2010 Net Sales Figures

Passing of Genmab A/S' Annual General Meeting

Genmab Announces Pipeline and Technology Update

GlaxoSmithKline Receives Conditional Marketing Authorization in the EU for Arzerra(TM) (ofatumumab)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application